131 related articles for article (PubMed ID: 2161034)
1. Progress toward developing a cytomegalovirus vaccine.
Marshall GS; Plotkin SA
Infect Dis Clin North Am; 1990 Jun; 4(2):283-98. PubMed ID: 2161034
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus vaccines: current status.
Starr SE
Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538
[TBL] [Abstract][Full Text] [Related]
3. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
[TBL] [Abstract][Full Text] [Related]
4. Immunoprophylaxis against cytomegalovirus disease.
Adler SP
Scand J Infect Dis Suppl; 1995; 99():105-9. PubMed ID: 8668931
[TBL] [Abstract][Full Text] [Related]
5. Current prospects for immunization against cytomegaloviral disease.
Adler SP
Infect Agents Dis; 1996 Jan; 5(1):29-35. PubMed ID: 8789597
[TBL] [Abstract][Full Text] [Related]
6. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.
Plotkin SA; Higgins R; Kurtz JB; Morris PJ; Campbell DA; Shope TC; Spector SA; Dankner WM
Transplantation; 1994 Dec; 58(11):1176-8. PubMed ID: 7992358
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
[TBL] [Abstract][Full Text] [Related]
8. Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine.
Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
Birth Defects Orig Artic Ser; 1984; 20(1):271-87. PubMed ID: 6329367
[No Abstract] [Full Text] [Related]
9. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
[TBL] [Abstract][Full Text] [Related]
10. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
[TBL] [Abstract][Full Text] [Related]
11. Progress toward an elusive goal: current status of cytomegalovirus vaccines.
Schleiss MR; Heineman TC
Expert Rev Vaccines; 2005 Jun; 4(3):381-406. PubMed ID: 16026251
[TBL] [Abstract][Full Text] [Related]
12. Progress in cytomegalovirus vaccine development.
Schleiss M
Herpes; 2005 Dec; 12(3):66-75. PubMed ID: 16393522
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with a Live Attenuated Cytomegalovirus Devoid of a Protein Kinase R Inhibitory Gene Results in Reduced Maternal Viremia and Improved Pregnancy Outcome in a Guinea Pig Congenital Infection Model.
Schleiss MR; Bierle CJ; Swanson EC; McVoy MA; Wang JB; Al-Mahdi Z; Geballe AP
J Virol; 2015 Oct; 89(19):9727-38. PubMed ID: 26178990
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Adler SP
J Clin Virol; 2006 Mar; 35(3):332-7. PubMed ID: 16387547
[TBL] [Abstract][Full Text] [Related]
15. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.
Zhang C; Buchanan H; Andrews W; Evans A; Pass RF
J Clin Virol; 2006 Mar; 35(3):338-42. PubMed ID: 16388984
[TBL] [Abstract][Full Text] [Related]
16. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection.
Schleiss MR; Lacayo JC; Belkaid Y; McGregor A; Stroup G; Rayner J; Alterson K; Chulay JD; Smith JF
J Infect Dis; 2007 Mar; 195(6):789-98. PubMed ID: 17299708
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial.
Balfour HH; Sachs GW; Welo P; Gehrz RC; Simmons RL; Najarian JS
Birth Defects Orig Artic Ser; 1984; 20(1):289-304. PubMed ID: 6329368
[No Abstract] [Full Text] [Related]
18. Human CMV vaccine trials: what if CMV caused a rash?
Adler SP
J Clin Virol; 2008 Mar; 41(3):231-6. PubMed ID: 18096431
[TBL] [Abstract][Full Text] [Related]
19. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.
Arvin AM; Fast P; Myers M; Plotkin S; Rabinovich R;
Clin Infect Dis; 2004 Jul; 39(2):233-9. PubMed ID: 15307033
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine.
Adler SP; Hempfling SH; Starr SE; Plotkin SA; Riddell S
Pediatr Infect Dis J; 1998 Mar; 17(3):200-6. PubMed ID: 9535246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
